Q3 2021 Investor Relations Results

Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Financial performance Innovation: Pipeline overview Innovation: Clinical trials Neuroscience Ophthalmology Respiratory & Allergy Oncology: Solid Tumors Hematology Biosimilars Global Health Abbreviations CRM IHD iscalimab - CD40 inhibitor Study Indication Phase Patients NCT03781414 CONTRAIL I (CCFZ533A2202) Liver transplantation Phase 2 128 Primary Outcome Measures Arms Intervention NCT03905525 TWINSS (CCFZ533B2201) Sjögren's syndrome Phase 2 260 Proportion of patients with composite event (BPAR, Graft Loss or Death) over 12 months Control/Standard of Care: TAC + MMF + Corticosteroids CFZ533 dose A+ MMF + Corticosteroids CFZ533 dose B + MMF + Corticosteroids Change in EULAR Sjögren's syndrome Disease Activity Index (ESSDAI) score and EULAR Sjögren's syndrome Patient Reported Index (ESSPRI) score Three dose arms of CFZ533 Placebo Target Patients Liver transplant recipients Read-out Milesstone(s) 2023 Publication 2023 80 Investor Relations | Q3 2021 Results Patients with Sjögren's syndrome 2022 2022 NOVARTIS | Reimagining Medicine

View entire presentation